The Biostatistics and Genetics Core (BGC) Component 2 will provide data processing, database coordination and maintenance, data analysis and statistical support for each of the other cores and projects within the Methamphetamine Abuse Research Center (MARC). Quantitative genetic analysis support will also be given to those Cores using mouse genetic models. This single unit serves as an important interface for the transmission of diverse types of data and processed information among core and project investigators. It assures that data and information from different cores and projects will be processed uniformly and in such a way as to allow for their smooth interface where appropriate. The environment provided by a single data management and biostatistics unit also facilitates the effective and timely return of processed data and information to the core and project investigators in support of their objectives. In addition, this Core will facilitate data sharing for investigators within and outside the center. This Core will continue to assist in the use of public databases and computer software, and provide the computer infrastructure for the microarray and QTL studies. Training in statistical and genetic methods and experimental design will also be provided on a one-on-one and as-needed basis. This Core will also develop new analytical programs tailored to the needs of MARC investigators, particularly newer clustering algorithms. As the Center continues to evolve, we will continue development of a central data warehouse for the MARC on our secure server.

Public Health Relevance

This Core supports the scientific activities of almost all other Cores and Components of the MARC, thus relevance stems from the impact of these other MARC units on the future mitigation or treatment of methamphetamine abuse in human drug abuse populations.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-EXL-T (02))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
United States
Zip Code
Grazier, Kyle L; Quanbeck, Andrew R; Oruongo, John et al. (2015) What Influences Participation in QI? A Randomized Trial of Addiction Treatment Organizations. J Healthc Qual 37:342-53
McCarty, Dennis; Bovett, Rob; Burns, Thomas et al. (2015) Oregon's strategy to confront prescription opioid misuse: a case study. J Subst Abuse Treat 48:91-5
Mitchell, Suzanne H (2014) Assessing delay discounting in mice. Curr Protoc Neurosci 66:Unit 8.30.
Ramaker, M J; Ford, M M; Phillips, T J et al. (2014) Differences in the reinstatement of ethanol seeking with ganaxolone and gaboxadol. Neuroscience 272:180-7
Hitchcock, Leah N; Cunningham, Christopher L; Lattal, K Matthew (2014) Cue configuration effects in acquisition and extinction of a cocaine-induced place preference. Behav Neurosci 128:217-27
Delamater, Andrew R; Lattal, K Matthew (2014) The study of associative learning: mapping from psychological to neural levels of analysis. Neurobiol Learn Mem 108:1-4
Eastwood, E C; Phillips, T J (2014) Morphine intake and the effects of naltrexone and buprenorphine on the acquisition of methamphetamine intake. Genes Brain Behav 13:226-35
Hartung, Daniel M; McCarty, Dennis; Fu, Rongwei et al. (2014) Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies. J Subst Abuse Treat 47:113-21
Raybuck, J D; Lattal, K M (2014) Differential effects of dorsal hippocampal inactivation on expression of recent and remote drug and fear memory. Neurosci Lett 569:1-5
Janowsky, Aaron; Eshleman, Amy J; Johnson, Robert A et al. (2014) Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro. Psychopharmacology (Berl) 231:2771-83

Showing the most recent 10 out of 67 publications